Nano-X Imaging Ltd.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $NNOX in the last 30 days.
See all $NNOX insider activity →Nano-X Imaging Ltd. (NNOX) reported preliminary Q3 revenue of $4.3–$4.4M, up from $3.4M YoY, and $26.0M in cash. Management indicated liquidity concerns, raising going-concern doubts. The company needs to secure funding or accelerate deployments to mitigate risks.
Nano-X Imaging's subsidiary, Nanox AI, signed a distribution deal with Technologic s.r.l. to sell HealthOST in Italy. This marks an early commercialization step for Nanox AI. Nano-X Imaging announced the agreement.
Nanox Imaging Ltd. (NASDAQ: NNOX) announced that its Nanox.ARC X system was selected as one of TIME’s Best Inventions of 2026. The system offers 3D imaging with up to 80% less radiation than CT scans. This is Nanox’s second appearance on TIME’s list, marking its first inclusion on the main list. The company plans to showcase the system at the RSNA 2026 Annual Meeting.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning NNOX (Nano-X Imaging Ltd.). Coverage has skewed bullish: 6 bullish, 1 neutral, and 2 bearish.
Recent NNOX coverage spans earnings, technology and financial news.
Guidance downgrade and liquidity warning likely pressure the stock.
The deal could provide incremental revenue and raise visibility in Europe.
Recognition may boost brand visibility and demand, supporting short-term price appreciation.
The compliance deadline creates delisting risk, likely pressuring the stock lower.
The new UK contract and Intel partnership expand Nanox's commercial and technical reach, likely boosting investor sentiment.
AlphAI scores every news story that mentions NNOX with an AI model for sentiment and relevance, and aggregates insider trades from Nano-X Imaging Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nano-X Imaging Ltd. (NNOX) reported preliminary Q3 revenue of $4.3–$4.4M, up from $3.4M YoY, and $26.0M in cash. Management indicated liquidity concerns, raising going-concern doubts. The company needs to secure funding or accelerate deployments to mitigate risks.
1 min readNano-X Imaging's subsidiary, Nanox AI, signed a distribution deal with Technologic s.r.l. to sell HealthOST in Italy. This marks an early commercialization step for Nanox AI. Nano-X Imaging announced the agreement.
1 min readNanox Imaging Ltd. (NASDAQ: NNOX) announced that its Nanox.ARC X system was selected as one of TIME’s Best Inventions of 2026. The system offers 3D imaging with up to 80% less radiation than CT scans. This is Nanox’s second appearance on TIME’s list, marking its first inclusion on the main list. The company plans to showcase the system at the RSNA 2026 Annual Meeting.
2 min readNano-X Imaging (NNOX) received a Nasdaq notice that its shares no longer meet the minimum bid-price requirement of $1.00. The company has until March 29, 2027, to regain compliance, with a potential 180-day extension if it transfers to Nasdaq Capital Market. NNOX is considering options to meet the requirement.
1 min readNanox.AI, a subsidiary of Nano-X Imaging Ltd. (NNOX), signed a 3-year UK reseller agreement with Vertec Scientific for its HealthOST bone solution. Separately, it partnered with Intel to optimize its AI framework for local hospital hardware. The company aims to leverage additional anatomical data from CT scans to support clinical evaluations. According to Nanox, 86,000 vertebral fragility fractures occur annually in the UK, many undiagnosed.
2 min readNanox reports Q2 revenue of $4.2 million, highlighting its integrated imaging ecosystem. The company aims to expand access to 3D imaging and diagnostics with its Nanox.ARC system, which is FDA-cleared. Nanox addresses global disparities in imaging technology access, with a focus on lower adoption barriers.
1 min readNano-X Imaging Ltd. (NNOX) is developing an integrated medical imaging platform combining hardware, AI, and cloud software for early disease detection. The company reported Q1 2026 revenue of $4.3M, up from $2.8M a year earlier. It is expanding through partnerships with healthcare organizations and licensing its technology.
2 min readSuesskind Dan S purchased 60,000 shares of Nano-X Imaging Ltd. (NNOX) at an average of $0.76 ($0.75–$0.76) across 2 trades on 2026-09-14.
1 min readNano-X Imaging (NNOX) reported Q2 revenue growth of 37% YoY to $4.2M, but also a $40.7M impairment charge and a 50% cash reduction in six months. The company plans to cut costs and outsource manufacturing. First reimbursement payments from a Philadelphia site ranged from $200 to $700 per claim. Cash reserves fell to $31.4M, raising concerns about the company's going concern status.
2 min readNanox (NASDAQ:NNOX) reported Q2 2026 revenue of $4.2M, up 37% YoY, driven by its acquired Nanox Health IT unit. However, a $40.7M impairment charge widened its GAAP net loss to $55.5M. Cash declined to $31.4M, though the company raised $8.5M post-quarter. Nanox aims to continue fundraising amid ongoing losses and restructuring efforts.
2 min read
